A detailed history of Principal Financial Group Inc transactions in Cellectis S.A. stock. As of the latest transaction made, Principal Financial Group Inc holds 411,800 shares of CLLS stock, worth $807,128. This represents 0.0% of its overall portfolio holdings.

Number of Shares
411,800
Previous 437,000 5.77%
Holding current value
$807,128
Previous $817,000 6.85%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$1.9 - $2.4 $47,880 - $60,480
-25,200 Reduced 5.77%
411,800 $873,000
Q2 2024

Jul 29, 2024

BUY
$1.86 - $3.35 $23,188 - $41,764
12,467 Added 2.94%
437,000 $817,000
Q1 2024

Apr 29, 2024

BUY
$2.41 - $3.09 $60,023 - $76,959
24,906 Added 6.23%
424,533 $1.13 Million
Q4 2023

Feb 07, 2024

SELL
$0.97 - $3.55 $249,263 - $912,254
-256,973 Reduced 39.14%
399,627 $1.23 Million
Q3 2023

Nov 02, 2023

SELL
$1.58 - $2.86 $16,496 - $29,861
-10,441 Reduced 1.57%
656,600 $1.04 Million
Q2 2023

Aug 07, 2023

SELL
$1.72 - $2.12 $1.2 Million - $1.47 Million
-694,819 Reduced 51.02%
667,041 $1.31 Million
Q1 2023

May 09, 2023

BUY
$1.83 - $3.84 $50,892 - $106,790
27,810 Added 2.08%
1,361,860 $2.63 Million
Q4 2022

Feb 09, 2023

SELL
$1.85 - $2.6 $17,421 - $24,484
-9,417 Reduced 0.7%
1,334,050 $2.8 Million
Q3 2022

Nov 09, 2022

SELL
$2.29 - $4.08 $11,095 - $19,767
-4,845 Reduced 0.36%
1,343,467 $3.08 Million
Q2 2022

Aug 10, 2022

BUY
$2.39 - $4.93 $319,272 - $658,583
133,587 Added 11.0%
1,348,312 $3.82 Million
Q1 2022

May 09, 2022

SELL
$3.45 - $8.77 $37,356 - $94,961
-10,828 Reduced 0.88%
1,214,725 $5.52 Million
Q4 2021

Feb 09, 2022

SELL
$8.01 - $12.84 $126,309 - $202,473
-15,769 Reduced 1.27%
1,225,553 $9.95 Million
Q3 2021

Nov 09, 2021

SELL
$11.94 - $16.09 $251,528 - $338,951
-21,066 Reduced 1.67%
1,241,322 $15.7 Million
Q2 2021

Aug 10, 2021

BUY
$14.36 - $20.93 $18.1 Million - $26.4 Million
1,262,388 New
1,262,388 $19.5 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $89.2M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.